Telaprevir

Type: Keyphrase
Name: Telaprevir
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Recent Trends in the Treatment of Chronic Hepatitis C

Sara C. Erickson, PharmD; Wenyi Qiu, MS; Crystal R. Maas-Patel, PharmD; Sharon M. Wang, PharmD, MS; and Bimal V. Patel, PharmD, MSSince the discovery of the hepatitis C virus (HCV) in 1989, the chronically infected population has experienced dynamic change. ... [Published American Journal of Managed Care - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Resistance and Response in HCV Genotype 1 Subtypes

Hepatitis C. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 19 March 2013).Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline ... [Published General Medicine eJournal - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Patients with severe telaprevir-related skin eruption can continue treatment

Patients with grade 3 widespread morbilliform eruption associated with telaprevir can continue their triple therapy as long as they are closely monitored, according to researchers from Massachusetts General Hospital.“With proper monitoring, it appears ... [Published Orthopedics Today - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

New hepatitis C drug treatment 'shows promise'

Hepatitis C is a virus that can infect and damage the liver "A new treatment for hepatitis C 'cured' 90% of patients with the infection in 12 weeks, scientists said," BBC News reports after a new drug protocol designed to target the protein that assists ... [Published NHS Choices - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 12 2014 - 1 reports

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Approximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver disease each year.1,2[1] Until recently, the standard of care for chronic HCV genotype 1 infection was a first-generation ... [Published DailyMe.Com - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

FDA Updates Raltegravir (Isentress) Labeling

“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir. “In drug interaction studies, raltegravir did not have a clinically meaningful ... [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 3 reports

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

More than 3 million people in the United States are chronically infected with the hepatitis C virus (HCV). 1,2 Although the number of new infections has been declining for decades, HCV-related morbidity and mortality are projected to continue rising for ... [Published New England Journal of Medicine - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Approximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver disease each year. Until recently, the standard of care for chronic HCV genotype 1 infection was a first-generation ... [Published The New England Journal of Medicine: Infectious ... - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

10 medical innovations set to reshape patient care this year

The Cleveland Clinic asked 100 of its top experts -- people who focus on patient care every day -- to offer insights on which medical breakthroughs are set to reshape healthcare this year. Here are their answers:10. Targeted therapy for cancerThere's ... [Published Boston Herald - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Triple therapy decreased SVR12 in mildly decompensated patients

Patients with a Child-Turcotte-Pugh scores greater than 6 who underwent protease inhibitor triple therapy experienced decreases in sustained virologic response at 12 weeks, according to data in a new study.Researchers conducted a multicenter study of ... [Published Orthopedics Today - Apr 08 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus

Hepatitis C virus (HCV) causes an infectious disease that manifests itself as liver inflammation, cirrhosis, and can lead to the development of liver cancer. Its NS3/4A serine protease is a potent target for drug design and development since it is responsible ... [Published Journal of Chemical Information and Modeling - Apr 01 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 1 reports

APASL: Simeprevir Matches Telprevir in Phase 3 Study, Gets Positive European Regulatory Opinion

The new hepatitis C virus (HCV) protease inhibitor simeprevir has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization in the European Union, Janssen R&D announced this week. ... [Published HIV and Hepatitis.com - Mar 25 2014]

Quotes

Hepatitis C is a virus that can infect and damage the liver "A new treatment for hepatitis C 'cured' 90% of patients with the infection in 12 weeks, scientists said" BBC News reports after a new drug protocol designed to target the protein that assists the spread of the virus through the body has shown promising...
"A single tablet regimen of sofosbuvir/ledipasvir administered once daily for 12 weeks is highly effective and well tolerated in treatment-naive, genotype 1, HCV-infected patients, including those with cirrhosis" the ION-1 researchers concluded
...Alessio Aghemo, Gastroenterology and Hepatology Unit, Ospedale Maggiore Policlinico, University of Milan. "The impressive SVR12 results seen are consistent with the results from AbbVie's phase II studies" he added

More Content

All (61) | News (55) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Previous Exposure to HCV Among Persons Born Dur... [Published General Medicine eJournal - Apr 18 2014]
Recent Trends in the Treatment of Chronic Hepat... [Published American Journal of Managed Care - Apr 17 2014]
Resistance and Response in HCV Genotype 1 Subtypes [Published General Medicine eJournal - Apr 17 2014]
HCV Genotype 3 -- The New Treatment Challenge [Published General Medicine eJournal - Apr 16 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
Patients with severe telaprevir-related skin er... [Published Orthopedics Today - Apr 16 2014]
Deadly Disease That's Curable If You're Rich [o... [Published Individual.com - Apr 15 2014]
New hepatitis C drug treatment 'shows promise' [Published NHS Choices - Apr 14 2014]
Sofosbuvir/ledipasvir coformulation cures more ... [Published Aidsmap - Apr 14 2014]
EASL 2014: Sofosbuvir + Ledipasvir Cures More t... [Published HIV and Hepatitis.com - Apr 13 2014]
EASL 2014: European Liver Specialists Recommend... [Published HIV and Hepatitis.com - Apr 13 2014]
Interferon-free triple regimen plus ribavirin e... [Published Orthopedics Today - Apr 12 2014]
ABT-450/r–Ombitasvir and Dasabuvir with Ribavir... [Published New England Journal of Medicine - Apr 12 2014]
Ledipasvir and Sofosbuvir for Untreated HCV Gen... [Published New England Journal of Medicine - Apr 12 2014]
New interferon-free, all-oral 3D regimen achiev... [Published EurekAlert! - Apr 12 2014]
European liver specialists recommend `mix-and-m... [Published Aidsmap - Apr 12 2014]
EASL updates recommendations for HCV management [Published Orthopedics Today - Apr 11 2014]
FDA Updates Raltegravir (Isentress) Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published DailyMe.Com - Apr 11 2014]
Treating Hepatitis C in Lower-Income Countries [Published New England Journal of Medicine - Apr 11 2014]
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for... [Published New England Journal of Medicine - Apr 11 2014]
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published New England Journal of Medicine - Apr 11 2014]
Retreatment of HCV with ABT-450/r-Ombitasvir an... [Published National AIDS Treatment Advocacy Project - Apr 11 2014]
88% of previous relapsers achieve hepatitis C c... [Published Aidsmap - Apr 11 2014]
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published The New England Journal of Medicine: Infectious ... - Apr 11 2014]
SAPPHIRE II: Ritonavir-boosted triple regimen p... [Published Orthopedics Today - Apr 10 2014]
EASL 2014: WHO Recommends Global Use of Newest ... [Published HIV and Hepatitis.com - Apr 10 2014]
WHO recommends global use of newest hepatitis C... [Published Aidsmap - Apr 09 2014]
Hepatitis C: counting the cost [Published The Nation - Thailand - Apr 09 2014]
10 medical innovations set to reshape patient c... [Published Boston Herald - Apr 08 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
FDA Updates Raltegravir (Isentress) Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir. “In drug interaction studies, raltegravir did not have a clinically meaningful ...
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published The New England Journal of Medicine: Infectious ... - Apr 11 2014]
Approximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver disease each year. Until recently, the standard of care for chronic HCV genotype 1 infection was a first-generation ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 11 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.